This content is machine translated Non-resectable BRAF-mutated melanoma 5-year data from COLUMBUS study support continued long-term benefits After five years of follow-up in the COLUMBUS study, it is clear that patients with non-resectable or metastatic melanoma with a BRAFV600 mutation benefit long-term from encorafenib in combination with…
